|
|
Latest Ovarian Cancer News
Olaparib Active Against Advanced Ovarian Cancer and Breast Cancer with BRCA Mutations (7/20/2010)
Previously treated advanced breast and ovarian cancer patients with BRCA1 or BRCA2 gene mutation may benefit from treatment with the oral investigational drug olaparib.
High Circulating Vitamin D Levels Don’t Reduce Risk of Less Common Cancers (7/12/2010)
High levels of vitamin D in the bloodstream do not appear to reduce the risk of seven less common cancers: endometrial, esophageal, stomach, ovarian, pancreatic, kidney, and non-Hodgkin’s lymphoma.
Combination of Trabectedin and Pegylated Liposomal Doxorubicin Modestly Delays Progression of Recurrent Ovarian Cancer (7/9/2010)
The combination of the investigational agent trabectedin with pegylated liposomal doxorubicin (PLD) resulted in a 1.5-month improvement in progression-free survival in women with recurrent ovarian cancer.
Olaparib Shows Promise in High-grade Serous Ovarian Cancer (6/16/2010)
Advanced serous ovarian cancer responds to single-agent treatment with olaparib, according to the results of a Phase II study presented at the 2010 annual meeting of the American Society of Clinical Oncology.
Promising Results for Ovarian Cancer Screening Strategy (6/3/2010)
In a study of postmenopausal women at average-risk of ovarian cancer, promising results were obtained with an ovarian cancer screening strategy that combined information about trends in CA-125 blood test results and age, followed as needed by transvaginal ultrasound and referral to a gynecologic oncologist. These results will be presented at the 2010 annual meeting of the American Society of Clinical Oncology (ASCO).
Ovarian Cancer News By Topic
Ovarian Cancer - Screening/PreventionHigh Circulating Vitamin D Levels Don’t Reduce Risk of Less Common Cancers (7/12/2010)
High levels of vitamin D in the bloodstream do not appear to reduce the risk of seven less common cancers: endometrial, esophageal, stomach, ovarian, pancreatic, kidney, and non-Hodgkin’s lymphoma.
Promising Results for Ovarian Cancer Screening Strategy (6/3/2010)
In a study of postmenopausal women at average-risk of ovarian cancer, promising results were obtained with an ovarian cancer screening strategy that combined information about trends in CA-125 blood test results and age, followed as needed by transvaginal ultrasound and referral to a gynecologic oncologist. These results will be presented at the 2010 annual meeting of the American Society of Clinical Oncology (ASCO).
One Step Closer to Early Detection of Ovarian Cancer (4/13/2010)
A four-biomarker screening assay detected 86% of early-stage ovarian cancers with a 98% specificity level; this leads researchers to conclude that the assay could eventually become the first-line test in a two-step strategy for early detection of the disease. The results of this study were published early online in the Journal of Clinical Oncology.
Test Available for Pre-surgical Evaluation of Ovarian Mass (3/11/2010)
For women who require surgery for an ovarian mass, the OVA1™ test may help identify the most appropriate type of surgeon. The test assesses the likelihood that cancer is present; when cancer is likely, surgery may best be performed by a gynecologic oncologist.
Regular Aspirin Use May Reduce Risk of Ovarian Cancer (2/17/2010)
According to results from the Iowa Women’s Health Study, regular aspirin use may reduce the risk of developing ovarian cancer but does not appear to affect the risk of endometrial cancer. These results were published in Cancer Epidemiology, Biomarkers, and Prevention.
Ovarian Cancer - Stage ISeptember Is National Ovarian Cancer Awareness Month (9/1/2009)
As the month of September brings ovarian cancer into focus, it’s time to increase public understanding about the disease, including its prevalence, approaches to screening and prevention, treatment options, and resources that offer updated ovarian cancer information throughout the year.
Fertility Preservation Appears to Be Safe for Young Women with Early-stage Ovarian Cancer (8/11/2009)
Preservation of the non-cancerous ovary and the uterus appears to be safe for young women with Stage IA or IC ovarian cancer and allows women to preserve their fertility. These results were published in Cancer.
Cancer Consultants Offers Free Subscriptions to Women&Cancer Magazine (12/1/2008)
Women&Cancer is the premier women’s health and wellness magazine. By covering all health and wellness issues with an emphasis on cancer prevention, early detection, management, and survivorship, Women&Cancer empowers women with regard to their own health and recognizes the unique role of women in the overall health of their family and friends.
Updates in the Management of Gynecologic Cancers (5/27/2008)
A Report from the 39th Annual Meeting of the Society of Gynecologic Oncologists
Ovarian Cancer National Alliance Announces Eleventh Annual Conference (4/9/2008)
This year the Ovarian Cancer National Alliance will hold their eleventh annual conference, titled “Creating Currents of Change,” on Tuesday, July 8 through Thursday, July 10 at the Omni Shoreham Hotel in Washington, D.C.
Ovarian Cancer - Stages II-IVOlaparib Shows Promise in High-grade Serous Ovarian Cancer (6/16/2010)
Advanced serous ovarian cancer responds to single-agent treatment with olaparib, according to the results of a Phase II study presented at the 2010 annual meeting of the American Society of Clinical Oncology.
Chemotherapy Drug Patupilone Fails in Advanced Ovarian Cancer (6/2/2010)
The chemotherapy drug patupilone (EPO906) has failed to show a survival advantage over Doxil®/Caelyx® (pegylated liposomal doxorubicin) in patients with advanced ovarian cancer that is resistant to platinum-based therapy. Novartis reported the results in a press release
Olaparib Active Against Advanced Ovarian Cancer in Women with BRCA Mutations (5/5/2010)
Olaparib, an investigational targeted therapy, resulted in a 61.5% response rate among women with platinum-sensitive, advanced ovarian cancer and a BRCA gene mutation. These results were recently published in the Journal of Clinical Oncology.
Avastin May Delay Progression of Ovarian Cancer (2/25/2010)
Among women with advanced ovarian cancer, treatment with a combination of Avastin® (bevacizumab) and chemotherapy, followed by maintenance treatment with Avastin, may result in better progression-free survival than chemotherapy alone.
September Is National Ovarian Cancer Awareness Month (9/1/2009)
As the month of September brings ovarian cancer into focus, it’s time to increase public understanding about the disease, including its prevalence, approaches to screening and prevention, treatment options, and resources that offer updated ovarian cancer information throughout the year.
Ovarian Cancer - RecurrentOlaparib Active Against Advanced Ovarian Cancer and Breast Cancer with BRCA Mutations (7/20/2010)
Previously treated advanced breast and ovarian cancer patients with BRCA1 or BRCA2 gene mutation may benefit from treatment with the oral investigational drug olaparib.
Combination of Trabectedin and Pegylated Liposomal Doxorubicin Modestly Delays Progression of Recurrent Ovarian Cancer (7/9/2010)
The combination of the investigational agent trabectedin with pegylated liposomal doxorubicin (PLD) resulted in a 1.5-month improvement in progression-free survival in women with recurrent ovarian cancer.
Olaparib Active Against Advanced Ovarian Cancer in Women with BRCA Mutations (5/5/2010)
Olaparib, an investigational targeted therapy, resulted in a 61.5% response rate among women with platinum-sensitive, advanced ovarian cancer and a BRCA gene mutation. These results were recently published in the Journal of Clinical Oncology.
Farletuzumab Shows Promise in Relapsed Ovarian Cancer (10/7/2009)
According to the results of a Phase II clinical trial, the investigational drug farletuzumab may have anticancer activity in the treatment of relapsed ovarian cancer when combined with chemotherapy. These results were presented at a European cancer conference.
Initiating Treatment Due to Elevated CA125 Marker Does Not Improve Survival in Recurrent Ovarian Cancer (6/2/2009)
Early treatment for recurrent ovarian cancer based on a rising CA125 marker does not appear to improve overall survival compared with treatment that is started upon presentation of symptoms, according to the results of a study presented at the 2009 annual meeting of the American Society of Clinical Oncology (ASCO) in Orlando, Florida.
|
|
